Purple Biotech (PPBT) has released an update.
Purple Biotech, a company focused on first-in-class oncology drug candidates, announced strong clinical progress with multiple data readouts expected in 2024. Their lead drug, CM24, is showing promising results in pancreatic cancer treatment, with a good safety profile and potential market opportunities due to significant unmet medical needs. The company maintains a robust cash balance and anticipates a cash runway into the first quarter of 2025.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
